We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Samaritan Pharmaceuticals a developer of innovative drugs announced it has contracted
with Sebiopharm, Paris, France, to perform preclinical pharmacokinetic studies
with its lead compounds.
Empowerment company Enaleni Pharmaceuticals, which will soon list on the JSE
Securities Exchange SA's AltX board, is extending its pharmaceutical manufacturing
-- finalising an agreement with a multinational company and plans to acquire
more pharmaceutical brands and companies, it said in its abridged prospectus.
Dutch biotechnology company Crucell N.V. announced that it has started an evaluation
program with Medarex, Inc., based in Princeton, New Jersey, to optimize the
application of Crucell's STAR technology in bioreactor culture.
Bioniche Life Sciences, a research-based, technology-driven human and animal
health biopharmaceutical company, announced that its specialty pharmaceutical
business unit, Bioniche Pharma Group Limited, has signed an exclusive agreement
with The Grunenthal Group for distribution of Bioniche's proprietary product,
Suplasyn in the Czech Republic, the Slovak Republic, Poland, and Russia.
Intra-Cellular Therapies (ITI),
a privately held biopharmaceutical company focusing on the development of new
therapeutics for neuropsychiatric and neurodegenerative disorders, announced
that it has been granted an exclusive, worldwide license to a family of preclinical
compounds from Bristol-Myers Squibb.
Amid continued economic and political strife, Zimbabwe's drug
market has all but collapsed, declining from US$50mn in 2001 to less than US$5mn
in 2004.
The lower house of Brazil's Congress has approved a long-delayed
new law that will allow the violation of patents on HIV/AIDS drugs manufactured
by three US drugmakers.